Vivakor Announces Mechanics of Dividend Distribution
08 Diciembre 2009 - 10:11AM
PR Newswire (US)
CORALVILLE, Iowa, Dec. 8 /PRNewswire-FirstCall/ -- Vivakor, Inc.
(OTC Bulletin Board: VIVK) today announced the mechanics for how
shareholders of record on December 1, 2009 will receive the
dividend of shares of common stock of HealthAmerica, Inc. that was
previously approved by Vivakor's Board of Directors. HealthAmerica
is a private Nevada corporation of which Vivakor owned
approximately 84% of the outstanding common shares on the record
date. The distribution date will be December 9, 2009, and will be
conducted as an "upon surrender" distribution. Each Vivakor
shareholder will be entitled to receive one share of HealthAmerica
common stock for each share of Vivakor common stock beneficially
owned on December 1, 2009. The shares of Health America being
distributed shall be recorded in the name of each Vivakor
shareholder of record on December 1, 2009 as a journal entry with
the transfer agent, Integrity Stock Transfer, located in Las Vegas,
Nevada. Any shareholder of Vivakor as of the record date, December
1, 2009, may request a certificate directly from the transfer
agent, or may simply request a confirmation that a journal entry of
the shares with the transfer agent. No other action is required by
the Vivakor shareholders to obtain their shares. About Vivakor,
Inc. Vivakor(TM) is a biomedical/biotechnology company with
transdisciplinary research that develops and acquires products in
the fields of molecular medicine, electro-optics, biological
handling and natural and formulary compounds, that extend or
improve life. More information can be found about Vivakor at
http://www.vivakor.com/. About HealthAmerica, Inc. HealthAmerica is
developing a patented, FDA 510(k) cleared, technology
(VIVASlices(TM)) that is expected to enhance the resolution of
images resulting from MRI. The underlying algorithm may also be
useful in determining blood flow velocity measures in imaged
tissues, which would be valuable in accessing areas of blood flow
constriction from plaques or other hematologic deposits. This
information could help physicians better diagnose, predict and
assess stroke and related diseases involving blood flow
obstruction. At the end of 2000, there were approximately 9,500 MRI
(magnetic resonance imaging) systems installed worldwide. While
changes in medical reimbursements have slowed the sale of new
machines, there is an increased demand for improved efficiency
(i.e. accelerated patient throughput) from current systems.
Additionally, intense competition between various medical
facilities and the rapid distribution of new advances in imaging
(such as MR angiographies, which allow evaluation of blood vessels
without any invasive procedure) puts additional pressure on MRI
because increased image quality requires additional time. Thus
there is a huge need for an application like VIVASlices that can
improve both throughput and image quality. FORWARD-LOOKING
STATEMENTS This press release may contain forward-looking
statements, including, but not limited to, statements regarding
Vivakor's and HealthAmerica's products and markets. Forward-looking
statements may be identified by the use of the words "anticipates,"
"expects," "intends," "plans," "should," "could," "would," "may,"
"will," "believes," "estimates," "potential," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, risks and uncertainties discussed in Vivakor's filings
with the Securities and Exchange Commission, which factors are
incorporated herein by reference. Readers are cautioned not to
place undue reliance on any of these forward-looking statements.
Vivakor undertakes no obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date of this press release or to reflect actual outcomes.
Contact: Vivakor, Inc. Matt Nicosia, 319-625-2172 DATASOURCE:
Vivakor, Inc. CONTACT: Matt Nicosia of Vivakor, Inc.,
+1-319-625-2172, Web Site: http://www.vivakor.com/
Copyright